New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme
Glioblastoma multiforme (GBM) is known as the most aggressive and prevalent brain tumor with a high mortality rate. It is reported in people who are as young as 10 years old to as old as over 70 years old, exhibiting inter and intra tumor heterogeneity. There are several genomic and proteomic invest...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2022-12-01
|
| Series: | Exploration of Targeted Anti-tumor Therapy |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/etat/Article/1002118 |
| _version_ | 1797975145456861184 |
|---|---|
| author | Manisha Singh Divya Jindal Vinayak Agarwal Deepanshi Pathak Mansi Sharma Pranav Pancham Shalini Mani Rachana |
| author_facet | Manisha Singh Divya Jindal Vinayak Agarwal Deepanshi Pathak Mansi Sharma Pranav Pancham Shalini Mani Rachana |
| author_sort | Manisha Singh |
| collection | DOAJ |
| description | Glioblastoma multiforme (GBM) is known as the most aggressive and prevalent brain tumor with a high mortality rate. It is reported in people who are as young as 10 years old to as old as over 70 years old, exhibiting inter and intra tumor heterogeneity. There are several genomic and proteomic investigations that have been performed to find the unexplored potential targets of the drug against GBM. Therefore, certain effective targets have been taken to further validate the studies embarking on the robustness in the field of medicinal chemistry followed by testing in clinical trials. Also, The Cancer Genome Atlas (TCGA) project has identified certain overexpressed targets involved in the pathogenesis of GBM in three major pathways, i.e., tumor protein 53 (p53), retinoblastoma (RB), and receptor tyrosine kinase (RTK)/rat sarcoma virus (Ras)/phosphoinositide 3-kinase (PI3K) pathways. This review focuses on the compilation of recent developments in the fight against GBM thus, directing future research into the elucidation of pathogenesis and potential cure for GBM. Also, it highlights the potential biomarkers that have undergone extensive research and have promising prognostic and predictive values. Additionally, this manuscript analyses the advent of gene therapy and immunotherapy, unlocking the way to consider treatment approaches other than, or in addition to, conventional chemo-radiation therapies. This review study encompasses all the relevant research studies associated with the pathophysiology, occurrence, diagnostic tools, and therapeutic intervention for GBM. It highlights the evolution of various therapeutic perspectives against GBM from the most conventional form of radiotherapy to the recent advancement of gene/cell/immune therapy. Further, the review focuses on various targeted therapies for GBM including chemotherapy sensitization, radiotherapy, nanoparticles based, immunotherapy, cell therapy, and gene therapy which would offer a comprehensive account for exploring several facets related to GBM prognostics. |
| first_indexed | 2024-04-11T04:30:57Z |
| format | Article |
| id | doaj.art-f051c1a0f7424afdb544ea54a5d9251d |
| institution | Directory Open Access Journal |
| issn | 2692-3114 |
| language | English |
| last_indexed | 2024-04-11T04:30:57Z |
| publishDate | 2022-12-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Targeted Anti-tumor Therapy |
| spelling | doaj.art-f051c1a0f7424afdb544ea54a5d9251d2022-12-29T08:42:12ZengOpen Exploration Publishing Inc.Exploration of Targeted Anti-tumor Therapy2692-31142022-12-013886788910.37349/etat.2022.00118New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiformeManisha Singh0https://orcid.org/0000-0002-0466-8986Divya Jindal1https://orcid.org/0000-0002-1041-8510Vinayak Agarwal2https://orcid.org/0000-0001-6239-5077Deepanshi Pathak3https://orcid.org/0000-0002-9394-0135Mansi Sharma4https://orcid.org/0000-0003-1720-8708Pranav Pancham5https://orcid.org/0000-0003-4332-5350Shalini Mani6https://orcid.org/0000-0003-2500-6962Rachana7https://orcid.org/0000-0002-8686-0372Department of Biotechnology, Jaypee Institute of Information Technology (JIIT), Noida 201301, IndiaDepartment of Biotechnology, Jaypee Institute of Information Technology (JIIT), Noida 201301, IndiaDepartment of Biotechnology, Jaypee Institute of Information Technology (JIIT), Noida 201301, IndiaDepartment of Biotechnology, Jaypee Institute of Information Technology (JIIT), Noida 201301, IndiaDepartment of Biotechnology, Jaypee Institute of Information Technology (JIIT), Noida 201301, IndiaDepartment of Biotechnology, Jaypee Institute of Information Technology (JIIT), Noida 201301, IndiaDepartment of Biotechnology, Jaypee Institute of Information Technology (JIIT), Noida 201301, IndiaDepartment of Biotechnology, Jaypee Institute of Information Technology (JIIT), Noida 201301, IndiaGlioblastoma multiforme (GBM) is known as the most aggressive and prevalent brain tumor with a high mortality rate. It is reported in people who are as young as 10 years old to as old as over 70 years old, exhibiting inter and intra tumor heterogeneity. There are several genomic and proteomic investigations that have been performed to find the unexplored potential targets of the drug against GBM. Therefore, certain effective targets have been taken to further validate the studies embarking on the robustness in the field of medicinal chemistry followed by testing in clinical trials. Also, The Cancer Genome Atlas (TCGA) project has identified certain overexpressed targets involved in the pathogenesis of GBM in three major pathways, i.e., tumor protein 53 (p53), retinoblastoma (RB), and receptor tyrosine kinase (RTK)/rat sarcoma virus (Ras)/phosphoinositide 3-kinase (PI3K) pathways. This review focuses on the compilation of recent developments in the fight against GBM thus, directing future research into the elucidation of pathogenesis and potential cure for GBM. Also, it highlights the potential biomarkers that have undergone extensive research and have promising prognostic and predictive values. Additionally, this manuscript analyses the advent of gene therapy and immunotherapy, unlocking the way to consider treatment approaches other than, or in addition to, conventional chemo-radiation therapies. This review study encompasses all the relevant research studies associated with the pathophysiology, occurrence, diagnostic tools, and therapeutic intervention for GBM. It highlights the evolution of various therapeutic perspectives against GBM from the most conventional form of radiotherapy to the recent advancement of gene/cell/immune therapy. Further, the review focuses on various targeted therapies for GBM including chemotherapy sensitization, radiotherapy, nanoparticles based, immunotherapy, cell therapy, and gene therapy which would offer a comprehensive account for exploring several facets related to GBM prognostics.https://www.explorationpub.com/Journals/etat/Article/1002118p53 pathwayretinoblastoma pathwayreceptor tyrosine kinase (rtk)/rat sarcoma virus (ras)/phosphoinositide 3-kinase (pi3k) pathwaytheranostic biomarkersimmune therapygene therapy |
| spellingShingle | Manisha Singh Divya Jindal Vinayak Agarwal Deepanshi Pathak Mansi Sharma Pranav Pancham Shalini Mani Rachana New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme Exploration of Targeted Anti-tumor Therapy p53 pathway retinoblastoma pathway receptor tyrosine kinase (rtk)/rat sarcoma virus (ras)/phosphoinositide 3-kinase (pi3k) pathway theranostic biomarkers immune therapy gene therapy |
| title | New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme |
| title_full | New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme |
| title_fullStr | New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme |
| title_full_unstemmed | New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme |
| title_short | New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme |
| title_sort | new phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme |
| topic | p53 pathway retinoblastoma pathway receptor tyrosine kinase (rtk)/rat sarcoma virus (ras)/phosphoinositide 3-kinase (pi3k) pathway theranostic biomarkers immune therapy gene therapy |
| url | https://www.explorationpub.com/Journals/etat/Article/1002118 |
| work_keys_str_mv | AT manishasingh newphasetherapeuticpursuitsfortargeteddrugdeliveryinglioblastomamultiforme AT divyajindal newphasetherapeuticpursuitsfortargeteddrugdeliveryinglioblastomamultiforme AT vinayakagarwal newphasetherapeuticpursuitsfortargeteddrugdeliveryinglioblastomamultiforme AT deepanshipathak newphasetherapeuticpursuitsfortargeteddrugdeliveryinglioblastomamultiforme AT mansisharma newphasetherapeuticpursuitsfortargeteddrugdeliveryinglioblastomamultiforme AT pranavpancham newphasetherapeuticpursuitsfortargeteddrugdeliveryinglioblastomamultiforme AT shalinimani newphasetherapeuticpursuitsfortargeteddrugdeliveryinglioblastomamultiforme AT rachana newphasetherapeuticpursuitsfortargeteddrugdeliveryinglioblastomamultiforme |